H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on scPharmaceuticals to $18 from $15 and keeps a Buy rating on the shares following the approval of Furoscix.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals to Participate in the Jefferies London Healthcare Conference
- scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
- scPharmaceuticals Stock (NASDAQ:SCPH) Slides, Even as FDA Approves Furoscix
- UPDATE – scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
- scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree